Heat Biologics, Inc. (NASDAQ:HTBX) Files An 8-K Material Modification to Rights of Security Holders

76

Heat Biologics, Inc. (NASDAQ:HTBX) Files An 8-K Material Modification to Rights of Security Holders
Item 3.03 Material Modification to Rights of Security Holders.

Proposal 4 — Increase in Authorized Shares of Common Stock

As described above in Item 3.03 of this Current Report on Form 8-K/A, the Company’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to effect the Increase. At the reconvened Annual Meeting, proxies representing 17,991,437 shares of the Common Stock, which represented a majority of the issued and outstanding shares of Common Stock as of the record date (May 8, 2017), voted for the Increase (Proposal 4). The Increase is described in greater detail in the Definitive Proxy Statement. The results of the voting for the Increase were as follows:

VotesFor

VotesAgainst

Abstentions

BrokerNon-Votes

17,991,437

5,193,132

129,282

Item 3.03 – Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.

Description

3.1

Certificate of Amendment to the Certificate of Incorporation of Heat Biologics, Inc., dated July 13, 2017


HEAT BIOLOGICS, INC. Exhibit
EX-3.1 2 htbx_ex3z1.htm CERTIFICATE OF AMENDMENT OF THE THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF HEAT BIOLOGICS,…
To view the full exhibit click here

About Heat Biologics, Inc. (NASDAQ:HTBX)

Heat Biologics, Inc. is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT). Using its ImPACT platform technology, the Company has developed HS-410 (vesigenurtacel-L) as a product candidate to treat non-muscle invasive bladder cancer (NMIBC), and HS-110 (viagenpumatucel-L), which is intended for use in combination with an anti-PD-1 checkpoint inhibitor, as a potential treatment for patients with non-small cell lung cancer (NSCLC). Using its ComPACT platform technology, it has developed HS-120 as a potential treatment for NSCLC. It is conducting a Phase II trial of HS-410 in patients with NMIBC, and a Phase Ib trial of HS-110, in combination with nivolumab (Opdivo) to treat patients with NSCLC.

An ad to help with our costs